Physician profile
Regina Dodis
NPI 1649297722
$8,955.53
in general payments reported to CMS, 2019-2025
48 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $1,474 · 2021: $2,295 · 2022: $777 · 2023: $797 · 2024: $954 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,830 · Education: $15.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,829.67 |
| Education | $15.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $853.79 | 2019-2025 | Repatha, Tepezza, Repatha |
| Abbott Laboratories | $761.39 | 2019-2024 | Freestyle Libre 2, Freestyle Libre 3, Octrode |
| Sanofi-Aventis U.S. LLC | $747.22 | 2019-2023 | |
| Insulet Corporation | $711.06 | 2019-2024 | Omnipod |
| Lilly USA, LLC | $613.96 | 2019-2025 | Jardiance, Mounjaro, Humulin |
| Dexcom, INC. | $578.13 | 2019-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $495.61 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $447.55 | 2019-2021 | |
| Corcept Therapeutics | $285.84 | 2019-2025 | Korlym |
| Medtronic Minimed, INC. | $269.72 | 2019-2020 | |
| Mannkind Corporation | $260.83 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $233.99 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $230.93 | 2023-2025 | Yorvipath |
| Cequr Corporation | $216.77 | 2024-2025 | Cequr Simplicity |
| Sequel Med Tech, LLC | $201.31 | 2025 | Twiist |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Dodis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.